We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Potential Clinical Utility of Amniotic Fluid Cells for RNA-Sequencing Demonstrated

Representation of human cells.
Credit: Arek Socha, Pixabay
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

A clinical research team from the Department of Paediatrics and Adolescent Medicine and the Department of Obstetrics and Gynaecology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong (HKUMed) leads the discovery of applying amniotic fluid cells obtained during 16-24 weeks of pregnancy as a novel sample type for RNA-sequencing in prenatal diagnosis to help more families with tailored clinical management. It is the first proof-of-concept study to demonstrate the potential clinical utility of amniotic fluid cells RNA-sequencing in the literature. The ground-breaking findings have been published in the leading academic journal, npj Genomic Medicine.


Rare diseases are usually genetic in origin. Although individually rare, collectively rare diseases were found to be 1 in 67 in the Hong Kong population, based on the team’s previous study. The identification of genetic cause in rare diseases can provide accurate counseling for better clinical management and future pregnancy planning, which is essential to support the patients. Current technologies for prenatal diagnosis are largely DNA-based, with a large proportion (60-70%) remaining undiagnosed, leading to clinical uncertainty and parental anxiety. Recently, RNA-sequencing has been found to increase diagnostic yield by 10% to 36%, however, none of these studies focused on prenatal diagnosis. In addition, in spite of the availability of a well-established large database cataloging the gene expression profile of different tissues for adults, a similar publicly-available dataset for amniotic fluid cells reflecting the embryological and fetal stage is lacking. Further study and research on RNA-sequencing in the prenatal setting is thus necessary.

Research findings

The research team demonstrated the potential clinical utility of amniotic fluid cells RNA-sequencing. A baseline for the gene expression profile of amniotic fluid cells was established by performing RNA-sequencing on over 50 amniotic fluid samples. Establishment of a gene expression profile is an essential step in applying RNA-sequencing to the current selected clinical diagnosis workflow. The researchers found that the number of well-expressed genes in amniotic fluid cells was comparable to other clinically accessible tissues commonly used for genetic diagnosis across different disease categories. The research team also compared RNA-sequencing data of four affected fetuses with structural congenital anomalies with the established baseline to detect potential outliers. In collaboration with the Technical University of Munich in Germany, a bioinformatics pipeline was adapted to enhance the detection of outliers for subsequent analysis. Further in-depth curation showed that outliers can be identified in genes associated with the corresponding structural congenital anomalies in all four affected fetuses. Identifying the outliers provides more evidence at the RNA level to help with diagnosis.

Significance of the study

The findings of this study have significant implications for solving undiagnosed rare diseases in Hong Kong. It is the first time that amniotic fluid cells RNA-sequencing is reported to provide potential clinical utility in prenatal diagnosis in literature. With the identification of the genetic cause, precision medicine such as tailored clinical management and preimplantation genetic diagnosis for families with family history is possible.

This study was selected as the "Reviewers’ Choice Abstract" at the American Society of Human Genetics (ASHG) Annual Meeting 2022, one of the largest conferences of its kind, in which scientists from around the world are selected to present their cutting-edge research findings collaboratively. "It is an honour for HKUMed poster to be selected and scored as the top 10% of poster abstracts in this prestigious international conference. RNA-sequencing has great potential in solving unexplained genetic disorders. We will continue to strengthen ties and collaborations with institutions in Hong Kong and abroad, contribute to international scientific research and bring benefits back to our local patients," said Dr. Brian Chung Hon-yin, clinical geneticist, clinical associate professor, Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, HKUMed.

Dr. Anita Kan Sik-yau, honorary clinical associate professor, Department of Obstetrics and Gynaecology, School of Clinical Medicine, HKUMed cum Deputy Laboratory Director of the Prenatal Diagnostic Laboratory at Tsan Yuk Hospital added, "On the memorable occasion of Tsan Yuk Hospital (TYH)’s 100th Anniversary, this study demonstrated TYH’s exceptional service for Hong Kong over the past century, and continuous effort to contribute to all those in need, alongside innovative research."

Reference: Lee M, Kwong AKY, Chui MMC, et al. Diagnostic potential of the amniotic fluid cells transcriptome in deciphering Mendelian disease: a proof-of-concept. npj Genom Med. 2022;7(1):74. doi: 10.1038/s41525-022-00347-4

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.